Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2016

By: Global Markets Direct
, Published: Dec-2016
, Product code: GMDHC8867IDB
Key Insights
    • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease).
    • The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    • The pipeline guide reviews key companies involved in Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    • The pipeline guide evaluates Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    • The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease)

Companies mentioned in this product:

Abivax SA AdAlta Ltd Advanced Genetic Systems Inc Akshaya Bio Inc AlbaJuna Therapeutics Allergan Plc Altor BioScience Corp Altravax Inc Amarna Therapeutics BV American Gene Technologies International Inc Amunix Operating Inc Antigen Express Inc Aphios Corp Apotex Inc Argos Therapeutics Inc Arno Therapeutics Inc Atreca Inc B Cell Design SAS BioClonetics Immunotherapeutics Inc Biological Mimetics Inc Biosantech SA Biotron Ltd Boehringer Ingelheim GmbH Bolder Biotechnology Inc Bristol-Myers Squibb Company C4X Discovery Holdings PLC Calimmune Inc CEL-SCI Corp Celgene Corp Celldex Therapeutics Inc Chipscreen Biosciences Ltd CompleGen Inc ConjuChem LLC ContraVir Pharmaceuticals Inc Critical Outcome Technologies Inc Curevac AG Cytodyn Inc Dong-A Socio Holdings Co Ltd Enzo Biochem Inc EpiVax Inc eTheRNA Immunotherapies NV Etubics Corp Evofem Inc FIT Biotech Oy Formune SL Fountain Biopharma Inc Frontier Biotechnologies Co Ltd Galmed Pharmaceuticals Ltd GeneCure LLC GeoVax Labs Inc Gilead Sciences Inc GlaxoSmithKline Plc Globeimmune Inc GW Pharmaceuticals Plc H-Phar SA Hadasit Medical Research Services & Development Ltd Hanmi Pharmaceuticals Co Ltd Heat Biologics Inc ID Pharma Co Ltd IGXBio Inc Immune Response BioPharma Inc Immune Therapeutics Inc ImmunoClin Corp Immunocore Ltd Immunotope Inc ImQuest Life Sciences Inc InnaVirVax SA Innovative Targeting Solutions Inc Inovio Pharmaceuticals Inc Japan Tobacco Inc Johnson & Johnson Karyopharm Therapeutics Inc KPI Therapeutics Inc Kymab Ltd Longevity Biotech Inc MacroGenics Inc Medestea Research & Production SpA Medivir AB Merck & Co Inc Mologen AG Mymetics Corp Myrexis Inc NanoViricides Inc Navigen Pharmaceuticals Inc NeED Pharma srl New World Laboratories Inc Novartis AG Omeros Corp Oncolys BioPharma Inc OncoNOx ApS Oncovir Inc Orbis Biosciences Inc Osel Inc OyaGen Inc PaxVax Inc Peregrine Pharmaceuticals Inc Pfizer Inc Pharis Biotec GmbH PharmatrophiX Inc Phoenix Biotechnology Inc PlantForm Corp Profectus BioSciences Inc RAPID Pharmaceuticals AG ReceptoPharm Inc Recombio SL Relmada Therapeutics Inc Rodos BioTarget GmbH Samjin Pharmaceutical Co Ltd Sangamo BioSciences Inc Sanofi Sanofi Pasteur SA Savoy Pharmaceuticals Inc Serometrix LLC Sigma-Tau SpA Sirenas Marine Discovery LLC Solon Eiendom ASA Spider Biotech Spring Bank Pharmaceuticals Inc Staidson (Beijing) Biopharmaceuticals Co Ltd Starpharma Holdings Ltd Sumagen Co Ltd Susavion Biosciences Inc Taiga Biotechnologies Inc TaiMed Biologics Inc Takara Bio Inc Takeda Pharmaceutical Company Ltd TechnoVax Inc TeneoBio Inc TetraLogic Pharmaceuticals Teva Pharmaceutical Industries Ltd TGV-Laboratories Theratechnologies Inc Theravectys SA Tomegavax Inc Transgene Biotek Ltd TVAX Biomedical Inc United Biomedical Inc Vaccibody AS Vault Pharma Inc VDA Pharma Inc VG Life Sciences Inc Vichem Chemie Research Ltd ViiV Healthcare Ltd Viriom Ltd ViroStatics srl XL-protein GmbH Zydus Cadila Healthcare Ltd
Table of Contents
Table of Contents
Table of Contents 2
Introduction 10
Human Immunodeficiency Virus (HIV) Infections (AIDS) Overview 11
Therapeutics Development 12
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics under Development by Companies 14
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics under Investigation by Universities/Institutes 27
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Products Glance 33
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Products under Development by Companies 37
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Products under Investigation by Universities/Institutes 57
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development 67
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment 214
Drug Profiles 244
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects 864
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products 912
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones 919
Appendix 930
Tables and Figures
List of Tables
Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2016 57
Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS) - Comparative Analysis, H2 2016 58
Number of Products under Development by Companies, H2 2016 60
Number of Products under Development by Companies, H2 2016 (Contd..1) 61
Number of Products under Development by Companies, H2 2016 (Contd..2) 62
Number of Products under Development by Companies, H2 2016 (Contd..3) 63
Number of Products under Development by Companies, H2 2016 (Contd..4) 64
Number of Products under Development by Companies, H2 2016 (Contd..5) 65
Number of Products under Development by Companies, H2 2016 (Contd..6) 66
Number of Products under Development by Companies, H2 2016 (Contd..7) 67
Number of Products under Development by Companies, H2 2016 (Contd..8) 68
Number of Products under Development by Companies, H2 2016 (Contd..9) 69
Number of Products under Development by Companies, H2 2016 (Contd..10) 70
Number of Products under Development by Companies, H2 2016 (Contd..11) 71
Number of Products under Investigation by Universities/Institutes, H2 2016 72
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 73
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 74
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 75
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 76
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 77
Comparative Analysis by Late Stage Development, H2 2016 78
Comparative Analysis by Clinical Stage Development, H2 2016 79
Comparative Analysis by Early Stage Development, H2 2016 80
Comparative Analysis by Unknown Stage Development, H2 2016 81
Products under Development by Companies, H2 2016 82
Products under Development by Companies, H2 2016 (Contd..1) 83
Products under Development by Companies, H2 2016 (Contd..2) 84
Products under Development by Companies, H2 2016 (Contd..3) 85
Products under Development by Companies, H2 2016 (Contd..4) 86
Products under Development by Companies, H2 2016 (Contd..5) 87
Products under Development by Companies, H2 2016 (Contd..6) 88
Products under Development by Companies, H2 2016 (Contd..7) 89
Products under Development by Companies, H2 2016 (Contd..8) 90
Products under Development by Companies, H2 2016 (Contd..9) 91
Products under Development by Companies, H2 2016 (Contd..10) 92
Products under Development by Companies, H2 2016 (Contd..11) 93
Products under Development by Companies, H2 2016 (Contd..12) 94
Products under Development by Companies, H2 2016 (Contd..13) 95
Products under Development by Companies, H2 2016 (Contd..14) 96
Products under Development by Companies, H2 2016 (Contd..15) 97
Products under Development by Companies, H2 2016 (Contd..16) 98
Products under Development by Companies, H2 2016 (Contd..17) 99
Products under Development by Companies, H2 2016 (Contd..18) 100
Products under Development by Companies, H2 2016 (Contd..19) 101
Products under Investigation by Universities/Institutes, H2 2016 102
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 103
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 104
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 105
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 106
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 107
Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 108
Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 109
Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 110
Products under Investigation by Universities/Institutes, H2 2016 (Contd..9) 111
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Abivax SA, H2 2016 112
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AdAlta Ltd, H2 2016 113
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Advanced Genetic Systems Inc, H2 2016 114
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Akshaya Bio Inc, H2 2016 115
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AlbaJuna Therapeutics, H2 2016 116
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Allergan Plc, H2 2016 117
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altor BioScience Corp, H2 2016 118
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altravax Inc, H2 2016 119
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amarna Therapeutics BV, H2 2016 120
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by American Gene Technologies International Inc, H2 2016 121
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amunix Operating Inc, H2 2016 122
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Antigen Express Inc, H2 2016 123
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Aphios Corp, H2 2016 124
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Apotex Inc, H2 2016 125
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Argos Therapeutics Inc, H2 2016 126
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Arno Therapeutics Inc, H2 2016 127
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Atreca Inc, H2 2016 128
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by B Cell Design SAS, H2 2016 129
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by BioClonetics Immunotherapeutics Inc, H2 2016 130
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biological Mimetics Inc, H2 2016 131
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biosantech SA, H2 2016 132
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biotron Ltd, H2 2016 133
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 134
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bolder Biotechnology Inc, H2 2016 135
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bristol-Myers Squibb Company, H2 2016 136
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by C4X Discovery Holdings PLC, H2 2016 137
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Calimmune Inc, H2 2016 138
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by CEL-SCI Corp, H2 2016 139
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Celgene Corp, H2 2016 140
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Celldex Therapeutics Inc, H2 2016 141
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Chipscreen Biosciences Ltd, H2 2016 142
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by CompleGen Inc, H2 2016 143
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ConjuChem LLC, H2 2016 144
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 145
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Critical Outcome Technologies Inc, H2 2016 146
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Curevac AG, H2 2016 147
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Cytodyn Inc, H2 2016 148
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 149
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Enzo Biochem Inc, H2 2016 150
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by EpiVax Inc, H2 2016 151
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by eTheRNA Immunotherapies NV, H2 2016 152
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Etubics Corp, H2 2016 153
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Evofem Inc, H2 2016 154
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by FIT Biotech Oy, H2 2016 155
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Formune SL, H2 2016 156
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Fountain Biopharma Inc, H2 2016 157
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Frontier Biotechnologies Co Ltd, H2 2016 158
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Galmed Pharmaceuticals Ltd, H2 2016 159
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GeneCure LLC, H2 2016 160
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GeoVax Labs Inc, H2 2016 161
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Gilead Sciences Inc, H2 2016 162
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GlaxoSmithKline Plc, H2 2016 163
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Globeimmune Inc, H2 2016 164
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GW Pharmaceuticals Plc, H2 2016 165
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by H-Phar SA, H2 2016 166
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 167
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 168
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Heat Biologics Inc, H2 2016 169
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ID Pharma Co Ltd, H2 2016 170
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by IGXBio Inc, H2 2016 171
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immune Response BioPharma Inc, H2 2016 172
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immune Therapeutics Inc, H2 2016 173
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ImmunoClin Corp, H2 2016 174
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immunocore Ltd, H2 2016 175
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immunotope Inc, H2 2016 176
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ImQuest Life Sciences Inc, H2 2016 177
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by InnaVirVax SA, H2 2016 178
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Innovative Targeting Solutions Inc, H2 2016 179
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 180
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Japan Tobacco Inc, H2 2016 181
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Johnson & Johnson, H2 2016 182
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 183
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by KPI Therapeutics Inc, H2 2016 184
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Kymab Ltd, H2 2016 185
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Longevity Biotech Inc, H2 2016 186
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by MacroGenics Inc, H2 2016 187
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Medestea Research & Production SpA, H2 2016 188
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Medivir AB, H2 2016 189
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Merck & Co Inc, H2 2016 190
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Mologen AG, H2 2016 191
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Mymetics Corp, H2 2016 192
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Myrexis Inc, H2 2016 193
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by NanoViricides Inc, H2 2016 194
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Navigen Pharmaceuticals Inc, H2 2016 195
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by NeED Pharma srl, H2 2016 196
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by New World Laboratories Inc, H2 2016 197
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Novartis AG, H2 2016 198
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Omeros Corp, H2 2016 199
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Oncolys BioPharma Inc, H2 2016 200
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by OncoNOx ApS, H2 2016 201
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Oncovir Inc, H2 2016 202
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Orbis Biosciences Inc, H2 2016 203
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Osel Inc, H2 2016 204
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by OyaGen Inc, H2 2016 205
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by PaxVax Inc, H2 2016 206
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 207
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Pfizer Inc, H2 2016 208
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Pharis Biotec GmbH, H2 2016 209
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by PharmatrophiX Inc, H2 2016 210
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Phoenix Biotechnology Inc, H2 2016 211
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by PlantForm Corp, H2 2016 212
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Profectus BioSciences Inc, H2 2016 213
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by RAPID Pharmaceuticals AG, H2 2016 214
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ReceptoPharm Inc, H2 2016 215
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Recombio SL, H2 2016 216
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Relmada Therapeutics Inc, H2 2016 217
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Rodos BioTarget GmbH, H2 2016 218
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 219
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sangamo BioSciences Inc, H2 2016 220
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sanofi, H2 2016 221
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sanofi Pasteur SA, H2 2016 222
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Savoy Pharmaceuticals Inc, H2 2016 223
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Serometrix LLC, H2 2016 224
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sigma-Tau SpA, H2 2016 225
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sirenas Marine Discovery LLC, H2 2016 226
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Solon Eiendom ASA, H2 2016 227
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Spider Biotech, H2 2016 228
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2016 229
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, H2 2016 230
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Starpharma Holdings Ltd, H2 2016 231
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sumagen Co Ltd, H2 2016 232
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Susavion Biosciences Inc, H2 2016 233
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Taiga Biotechnologies Inc, H2 2016 234
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TaiMed Biologics Inc, H2 2016 235
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Takara Bio Inc, H2 2016 236
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 237
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TechnoVax Inc, H2 2016 238
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TeneoBio Inc, H2 2016 239
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TetraLogic Pharmaceuticals, H2 2016 240
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 241
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TGV-Laboratories, H2 2016 242
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Theratechnologies Inc, H2 2016 243
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Theravectys SA, H2 2016 244
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Tomegavax Inc, H2 2016 245
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Transgene Biotek Ltd, H2 2016 246
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TVAX Biomedical Inc, H2 2016 247
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by United Biomedical Inc, H2 2016 248
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Vaccibody AS, H2 2016 249
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Vault Pharma Inc, H2 2016 250
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by VDA Pharma Inc, H2 2016 251
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by VG Life Sciences Inc, H2 2016 252
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Vichem Chemie Research Ltd, H2 2016 253
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ViiV Healthcare Ltd, H2 2016 254
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Viriom Ltd, H2 2016 255
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ViroStatics srl, H2 2016 256
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by XL-protein GmbH, H2 2016 257
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 258
Assessment by Monotherapy Products, H2 2016 259
Assessment by Combination Products, H2 2016 260
Number of Products by Stage and Target, H2 2016 262
Number of Products by Stage and Mechanism of Action, H2 2016 274
Number of Products by Stage and Route of Administration, H2 2016 286
Number of Products by Stage and Molecule Type, H2 2016 288
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H2 2016 909
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..1), H2 2016 910
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..2), H2 2016 911
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..3), H2 2016 912
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..4), H2 2016 913
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..5), H2 2016 914
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..6), H2 2016 915
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..7), H2 2016 916
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..8), H2 2016 917
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..9), H2 2016 918
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..10), H2 2016 919
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..11), H2 2016 920
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..12), H2 2016 921
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..13), H2 2016 922
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..14), H2 2016 923
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..15), H2 2016 924
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..16), H2 2016 925
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..17), H2 2016 926
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..18), H2 2016 927
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..19), H2 2016 928
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..20), H2 2016 929
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..21), H2 2016 930
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..22), H2 2016 931
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..23), H2 2016 932
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..24), H2 2016 933
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..25), H2 2016 934
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..26), H2 2016 935
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..27), H2 2016 936
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..28), H2 2016 937
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..29), H2 2016 938
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..30), H2 2016 939
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..31), H2 2016 940
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..32), H2 2016 941
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..33), H2 2016 942
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..34), H2 2016 943
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..35), H2 2016 944
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..36), H2 2016 945
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..37), H2 2016 946
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..38), H2 2016 947
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..39), H2 2016 948
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..40), H2 2016 949
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..41), H2 2016 950
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..42), H2 2016 951
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..43), H2 2016 952
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..44), H2 2016 953
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..45), H2 2016 954
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..46), H2 2016 955
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects (Contd..47), H2 2016 956
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products, H2 2016 957
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..1), H2 2016 958
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..2), H2 2016 959
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..3), H2 2016 960
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..4), H2 2016 961
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..5), H2 2016 962
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products (Contd..6), H2 2016 9

List of Figures
Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2016 57
Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS) - Comparative Analysis, H2 2016 58
Number of Products under Development by Companies, H2 2016 59
Number of Products under Investigation by Universities/Institutes, H2 2016 72
Comparative Analysis by Late Stage Development, H2 2016 78
Comparative Analysis by Clinical Stage Development, H2 2016 79
Comparative Analysis by Early Stage Products, H2 2016 80
Assessment by Monotherapy Products, H2 2016 259
Assessment by Combination Products, H2 2016 260
Number of Products by Top 10 Targets, H2 2016 261
Number of Products by Stage and Top 10 Targets, H2 2016 261
Number of Products by Top 10 Mechanism of Actions, H2 2016 273
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 273
Number of Products by Top 10 Routes of Administration, H2 2016 285
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 285
Number of Products by Top 10 Molecule Types, H2 2016 287
Number of Products by Stage and Top 10 Molecule Types, H2 2016 287
Sample Pages

Request Sample Pages

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2016
By: Global Markets Direct
Published: Dec 2016
Contact Details


Download Brochure

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus Infections (AIDS) – Pipeline Review, H2 2016, provides an overview of the Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus Infections (AIDS) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 17, 43, 45, 2, 108, 75 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 15, 15, 51 and 67 molecules, respectively.

Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Synopsis

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease)

Reasons To Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Quick Overview

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus Infections (AIDS) – Pipeline Review, H2 2016, provides an overview of the Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline landscape.

More information about Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2016

For more information on this report or to speak to one of our experts

Call us on +44(0)20 7936 6830 or Email us

mail

For more information
on this report or to speak to one of our experts

Email us or call us on
+44(0)20 7936 6830

Purchase

Site License - This allows anybody within a business at the same site to view the report.

Single-user - This allows only one person to view the report.

Enterprise License -  This allows anybody globally within the organisation to view the report.

Preview Report

For a free preview of this report please complete our simple form.

Request
mail

Read our latest
Industry Insights Blog
and stay informed